Vascular Signalling Laboratory, ProCURE, Oncobell Program, Institut d´Investigació Biomèdica de Bellvitge (IDIBELL), Gran Via de l'Hospitalet 199, 08908, L´Hospitalet de Llobregat, Barcelona, Spain.
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
Nat Commun. 2018 Nov 16;9(1):4826. doi: 10.1038/s41467-018-07172-3.
Angiogenesis is a dynamic process relying on endothelial cell rearrangements within vascular tubes, yet the underlying mechanisms and functional relevance are poorly understood. Here we show that PI3Kα regulates endothelial cell rearrangements using a combination of a PI3Kα-selective inhibitor and endothelial-specific genetic deletion to abrogate PI3Kα activity during vessel development. Quantitative phosphoproteomics together with detailed cell biology analyses in vivo and in vitro reveal that PI3K signalling prevents NUAK1-dependent phosphorylation of the myosin phosphatase targeting-1 (MYPT1) protein, thereby allowing myosin light chain phosphatase (MLCP) activity and ultimately downregulating actomyosin contractility. Decreased PI3K activity enhances actomyosin contractility and impairs junctional remodelling and stabilization. This leads to overstretched endothelial cells that fail to anastomose properly and form aberrant superimposed layers within the vasculature. Our findings define the PI3K/NUAK1/MYPT1/MLCP axis as a critical pathway to regulate actomyosin contractility in endothelial cells, supporting vascular patterning and expansion through the control of cell rearrangement.
血管生成是一个依赖于血管管腔内内皮细胞重排的动态过程,但其中的潜在机制和功能相关性还知之甚少。在这里,我们展示了 PI3Kα 通过使用 PI3Kα 选择性抑制剂和内皮细胞特异性基因缺失的组合来调节内皮细胞的重排,从而在血管发育过程中消除 PI3Kα 的活性。定量磷酸蛋白质组学以及体内和体外的详细细胞生物学分析表明,PI3K 信号阻止了 NUAK1 依赖性肌球蛋白磷酸酶靶蛋白 1(MYPT1)蛋白的磷酸化,从而允许肌球蛋白轻链磷酸酶(MLCP)的活性,并最终下调肌动球蛋白收缩性。PI3K 活性的降低增强了肌动球蛋白的收缩性,并损害了连接重排和稳定。这导致内皮细胞过度拉伸,无法正确吻合,并在脉管系统内形成异常的重叠层。我们的研究结果将 PI3K/NUAK1/MYPT1/MLCP 轴定义为调节内皮细胞肌动球蛋白收缩性的关键途径,通过控制细胞重排来支持血管形态发生和扩张。